Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
Beijing, China. In Bmc Cancer, 2014
New resistant variants were identified in multiple genes including PRDM2, PRG4, MUC4, DSPP, DPCR1, RP1L1, MX2, POTEF, C1orf170, and KRTAP10-3.
Neuroinformatic analyses of common and distinct genetic components associated with major neuropsychiatric disorders.
Jerusalem, Israel. In Front Neurosci, 2013
The most widely shared subset of genes-common to five of six disorders-included ANK3, AS3MT, CACNA1C, CACNB2, CNNM2, CSMD1, DPCR1, ITIH3, NT5C2, PPP1R11, SYNE1, TCF4, TENM4, TRIM26, and ZNRD1.
Blood transcriptomic biomarkers in adult primary care patients with major depressive disorder undergoing cognitive behavioral therapy.
Chicago, United States. In Transl Psychiatry, 2013
Blood transcript levels of nine markers of ADCY3, DGKA, FAM46A, IGSF4A/CADM1, KIAA1539, MARCKS, PSME1, RAPH1 and TLR7, differed significantly between participants with MDD (N=32) and ND controls (N=32) at baseline (q< 0.05).
Gene expression profiles for predicting the efficacy of the anticancer drug 5-fluorouracil in breast cancer.
Kao-hsiung, Taiwan. In Dna Cell Biol, 2010
The experimental results demonstrated that FAM46A, IL18, CCL28, TNF, CXCL2, PLEKHA8, HRAS, FDXR, and CHI3L1 genes showed statistically significant differential expression between primary breast cancer culture cells that respond and nonrespond to 5-FU.